<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04663724</url>
  </required_header>
  <id_info>
    <org_study_id>8072</org_study_id>
    <nct_id>NCT04663724</nct_id>
  </id_info>
  <brief_title>Computer - Based Treatment for Social Anxiety Disorder</brief_title>
  <official_title>Computer-Based Treatment for Social Anxiety Disorder, A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mclean Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tel Aviv University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study is a controlled trial that seeks to examine the feasibility, acceptability,&#xD;
      mechanism, and efficacy of a recently developed computer-based therapy in individuals with&#xD;
      social anxiety disorder (SAD)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized clinical trial examines the feasibility, acceptability, mechanism, and&#xD;
      relative efficacy of two forms of a recently developed 4-week/8-session computer-based&#xD;
      therapy in individuals with social anxiety disorder (SAD). The purpose of this study is to&#xD;
      assess whether a brief computer-based research treatment, provided in 30 minutes sessions,&#xD;
      helps improve social anxiety symptoms, and by what mechanism. The study will also assess the&#xD;
      effect of research treatments on brain activity using magnetic resonance imaging (MRI).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Total Score of Liebowitz Social Anxiety Scale (LSAS)</measure>
    <time_frame>From baseline up to Month 4</time_frame>
    <description>Clinician-rated scale scoring anxiety (0, none to 3, severe) and avoidance (0,none to 3, severe) in 24 social situations for a total score of 0 to 144. Higher scores indicate greater social anxiety.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Total Score of Quality of Life Enjoyment &amp; Satisfaction Questionnaire</measure>
    <time_frame>From baseline up to Month 4</time_frame>
    <description>Quality of Life Enjoyment &amp; Satisfaction Questionnaire (Q-LES-Q): self-rated assessment of quality of life. 16 items related to life quality, each rated on a score of 1 (very poor) to 5 (very good), with a minimum total score of 16, and a maximum total score of 80.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Total Score of Social Phobia Inventory (SPIN)</measure>
    <time_frame>Baseline to Month 4</time_frame>
    <description>The Social Phobia Inventory (SPIN) is a self-rated questionnaire used to assess severity of social anxiety disorder. 17 items related to social anxiety each rated on a score of 0 to 4, with a minimum total score of 0 (least social anxiety), and a maximum total score of 68 (most social anxiety).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression-Change Scale</measure>
    <time_frame>Baseline to Month 4</time_frame>
    <description>Clinical Global Impression-Change Scale: An observer rating of overall clinical change, with rating from 1 (very much improved) to 7 (very much worse). Responder category is defined by a score of 1 or 2.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Social Anxiety Disorder</condition>
  <arm_group>
    <arm_group_label>Experimental Computer-Based Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A 4-week (8-sessions) course of computer-based treatment. Participants will receive treatment twice a week for four weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator Computer-Based Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A 4-week (8-sessions) course of computer-based treatment. Participants will receive treatment twice a week for four weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Computer-Based Treatment</intervention_name>
    <description>A 4-week (8 30-minute sessions) course of computer-based treatment involving viewing pictures of faces while music may play. Participants will receive research treatment twice a week.</description>
    <arm_group_label>Comparator Computer-Based Treatment</arm_group_label>
    <arm_group_label>Experimental Computer-Based Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females between the ages of 18 to 60&#xD;
&#xD;
          -  Current primary diagnosis of SAD&#xD;
&#xD;
          -  Score of at least 50 on the Liebowitz Social Anxiety Scale (self-rated version)&#xD;
&#xD;
          -  Fluent in English&#xD;
&#xD;
          -  Willing and able to give informed written consent&#xD;
&#xD;
          -  Ability to participate responsibly in the protocol&#xD;
&#xD;
          -  Normal or corrected-to-normal vision&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Present or past psychotic episode, psychotic disorder, schizophrenia, schizoaffective&#xD;
             disorder, or bipolar disorder&#xD;
&#xD;
          -  Current severe depression&#xD;
&#xD;
          -  Suicidal ideation or behavior&#xD;
&#xD;
          -  Current diagnosis of post-traumatic stress disorder, obsessive-compulsive disorder,&#xD;
             bipolar disorder, manic episode or tic disorder&#xD;
&#xD;
          -  Current or past organic mental disorder, seizure disorder, epilepsy or brain injury&#xD;
&#xD;
          -  Current unstable or untreated medical illness&#xD;
&#xD;
          -  Severe alcohol use disorder, severe cannabis use disorder, and any severity of other&#xD;
             substance use disorder (except nicotine use disorders)&#xD;
&#xD;
          -  Use of psychiatric medication in the past month other than a stable dose of selective&#xD;
             serotonin reuptake inhibitors (SSRIs) for at least 3 months&#xD;
&#xD;
          -  Any concurrent cognitive behavioral therapy or other psychotherapy that was initiated&#xD;
             in the past 3 months&#xD;
&#xD;
          -  Pregnancy, or plans to become pregnant during the period of the study (will be&#xD;
             assessed by urine)&#xD;
&#xD;
          -  Contraindication to MRI scanning (Paramagnetic metallic implants or devices&#xD;
             contraindicating magnetic resonance imaging or any other non-removable paramagnetic&#xD;
             metal in the body)&#xD;
&#xD;
               1. pacemaker&#xD;
&#xD;
               2. paramagnetic metallic prosthesis&#xD;
&#xD;
               3. surgical clips&#xD;
&#xD;
               4. shrapnel&#xD;
&#xD;
               5. necessity for constant medicinal patch&#xD;
&#xD;
               6. some tattoos&#xD;
&#xD;
          -  Inability to tolerate MRI scanning procedures (i.e., severe obesity, claustrophobia)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>FRANKLIN SCHNEIER, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York State Psychiatric Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Franklin Schneier, MD</last_name>
    <phone>6467748041</phone>
    <email>franklin.schneier@nyspi.columbia.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>1051 Riverside Drive</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bret R Rutherford, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 5, 2020</study_first_submitted>
  <study_first_submitted_qc>December 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2020</study_first_posted>
  <last_update_submitted>March 11, 2021</last_update_submitted>
  <last_update_submitted_qc>March 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York State Psychiatric Institute</investigator_affiliation>
    <investigator_full_name>Franklin Schneier</investigator_full_name>
    <investigator_title>Director, Anxiety Disorders Clinic</investigator_title>
  </responsible_party>
  <keyword>Attention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Phobia, Social</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be shared through the National Database for Clinical Trials related to Mental Illness (NDCT). We will obtain information needed to generate a Global Unique Identifier (GUID) for each participant (sex, first name, last name, middle name, date of birth, and city/municipality of birth). Raw data will be submitted semi-annually every January 15 and July 15, and prior to the end of each grant.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Beginning 12 months after completion of study assessments</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

